ES8609275A1 - Un procedimiento para preparar un derivado de pirimidina - Google Patents

Un procedimiento para preparar un derivado de pirimidina

Info

Publication number
ES8609275A1
ES8609275A1 ES543047A ES543047A ES8609275A1 ES 8609275 A1 ES8609275 A1 ES 8609275A1 ES 543047 A ES543047 A ES 543047A ES 543047 A ES543047 A ES 543047A ES 8609275 A1 ES8609275 A1 ES 8609275A1
Authority
ES
Spain
Prior art keywords
alkyl
aryl
significance
phenyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES543047A
Other languages
English (en)
Other versions
ES543047A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fisons Ltd
Original Assignee
Fisons Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB848412184A external-priority patent/GB8412184D0/en
Priority claimed from GB858500417A external-priority patent/GB8500417D0/en
Application filed by Fisons Ltd filed Critical Fisons Ltd
Publication of ES543047A0 publication Critical patent/ES543047A0/es
Publication of ES8609275A1 publication Critical patent/ES8609275A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE DERIVADOS DE PIRIMIDINA. COMPRENDE: A) HACER REACCIONAR UN COMPUESTO DE FORMULA (II) CON UN COMPUESTO DE FORMULA (III), EN PIRIDINA COMO DISOLVENTE, ENTRE 0 Y 1151C, PARA OBTENER UN COMPUESTO DE FORMULA (I); Y B) TRANSFORMAR EL PRODUCTO DE A) EN UNA SAL FARMACEUTICAMENTE ACEPTABLE. SIENDO: R Y R3, INCOMPATIBLES, H, FENILO O ALQUILO DE C 1 A 6; R1 Y R2, R3, R4 Y R5, INDEPENDIENTE, ANILLO PIRIDINILO, PIRIMIDINILO Y OTROS; UNO DE LOS ENLACES ---, DOBLE Y EL OTRO SENCILLO. SE UTILIZA PARA ESTIMULAR LA INMUNIDAD EN EL TRATAMIENTO DEL S.I.D.A. Y ENFERMEDADES INFECCIOSAS.
ES543047A 1984-05-12 1985-05-10 Un procedimiento para preparar un derivado de pirimidina Expired ES8609275A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB848412184A GB8412184D0 (en) 1984-05-12 1984-05-12 Biologically active nitrogen heterocycles
GB858500417A GB8500417D0 (en) 1985-01-08 1985-01-08 Biologically active nitrogen heterocycles
EP85302902A EP0164204A1 (en) 1984-05-12 1985-04-25 Novel pharmaceutically useful pyrimidines

Publications (2)

Publication Number Publication Date
ES543047A0 ES543047A0 (es) 1986-07-16
ES8609275A1 true ES8609275A1 (es) 1986-07-16

Family

ID=26287736

Family Applications (1)

Application Number Title Priority Date Filing Date
ES543047A Expired ES8609275A1 (es) 1984-05-12 1985-05-10 Un procedimiento para preparar un derivado de pirimidina

Country Status (9)

Country Link
EP (1) EP0164204A1 (es)
AU (1) AU4227685A (es)
DK (1) DK203985A (es)
ES (1) ES8609275A1 (es)
FI (1) FI851837L (es)
GR (1) GR851131B (es)
IL (1) IL75147A0 (es)
NO (1) NO851877L (es)
PT (1) PT80432B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
DE3751742T3 (de) † 1986-01-13 2002-11-21 American Cyanamid Co 4,5,6-Substituierte 2-Pyrimidinamine
GB8903592D0 (en) * 1989-02-16 1989-04-05 Boots Co Plc Therapeutic agents
US5064963A (en) * 1990-04-25 1991-11-12 American Cyanamid Company Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines
US5356898A (en) * 1991-01-31 1994-10-18 Warner-Lambert Company Substituted 4,6-di-tertiary-butyl 5-hydroxy-pyrimidines
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5248682A (en) * 1991-01-31 1993-09-28 Warner-Lambert Company 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
US5196431A (en) * 1992-02-24 1993-03-23 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
US5276186A (en) 1992-03-11 1994-01-04 Ciba-Geigy Corporation Process for the production of guanidine derivatives
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
EP0672041B1 (en) * 1993-10-01 2001-11-14 Novartis AG Pharmacologically active pyridine derivatives and processes for the preparation thereof
CA2148931A1 (en) * 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2001072745A1 (en) 2000-03-29 2001-10-04 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders
MXPA04004176A (es) * 2001-11-01 2004-09-06 Janssen Pharmaceutica Nv Derivados de aminobenzamida como inhibidores de cinasa 3beta de glicogeno sintasa.
US7514445B2 (en) 2001-11-01 2009-04-07 Janssen Pharmaceutica N.V. Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors)
AR038368A1 (es) 2002-02-01 2005-01-12 Novartis Ag Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
WO2005012262A1 (en) 2003-07-30 2005-02-10 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
EP1732541A4 (en) * 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
MX2007002169A (es) 2004-08-27 2007-08-14 Cyclacel Ltd Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
ATE534293T1 (de) 2005-09-27 2011-12-15 Irm Llc Diarylaminhaltige verbindungen und zusammensetzungen und deren verwendung als modulatoren von c-kit-rezeptoren
GB0606774D0 (en) * 2006-04-03 2006-05-10 Novartis Ag Organic compounds
KR101122481B1 (ko) 2007-05-04 2012-02-29 아이알엠 엘엘씨 Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물
WO2009026204A1 (en) 2007-08-22 2009-02-26 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
KR101218926B1 (ko) * 2007-08-22 2013-01-04 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
EP2299823A1 (en) * 2008-05-19 2011-03-30 The University of Tennessee Research Foundation Pyrimidine non-classical cannabinoid compounds and related methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3496179A (en) * 1967-10-11 1970-02-17 Pfizer & Co C 2-amino-3,4-dihydroquinazolines
US3663706A (en) * 1969-09-29 1972-05-16 Pfizer Use of 2,4-diaminoquinazolines as hypotensive agents
CA961855A (en) * 1969-10-16 1975-01-28 Eli Lilly And Company Immunosuppressants and anti-viral agents
US3900476A (en) * 1973-05-17 1975-08-19 Upjohn Co 2(2'-pyrimidylamino)quinazolines and their preparation
US4010269A (en) * 1975-06-16 1977-03-01 The Upjohn Company Antiviral quinazoline compositions and methods of use
DE3220118A1 (de) * 1982-05-28 1983-12-01 Bayer Ag, 5090 Leverkusen Alkylenverbrueckte guanidinothiazolderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
DK203985A (da) 1985-11-13
FI851837A0 (fi) 1985-05-09
EP0164204A1 (en) 1985-12-11
PT80432B (en) 1987-04-16
AU4227685A (en) 1985-11-14
GR851131B (es) 1985-11-25
PT80432A (en) 1985-06-01
ES543047A0 (es) 1986-07-16
NO851877L (no) 1985-11-13
DK203985D0 (da) 1985-05-08
IL75147A0 (en) 1985-09-29
FI851837L (fi) 1985-11-13

Similar Documents

Publication Publication Date Title
ES8609275A1 (es) Un procedimiento para preparar un derivado de pirimidina
DK204085A (da) Pyrazolderivater, deres fremstilling og farmaceutiske anvendelse
ZA842797B (en) Naphthoquinone derivatives
ATE26216T1 (de) Zusammensetzungen mit gehalt an interferon und ihre therapeutische anwendung.
GB1290818A (es)
MY8600695A (en) After-treatment of dyeings made with disazo compounds
IE892596L (en) Arylalkyl-amines and -amides having anticonvulsant and¹neuroprotective properties
FR2549049B1 (fr) Nouvelles amidines, leur procede de preparation et leur application therapeutique
NO954139D0 (no) Kinoksaliner, deres fremstilling og anvendelse
ES327089A1 (es) Un metodo para preparar alfa-ditiosemicarbazonas.
ES2002617A6 (es) Un procedimiento para la preparacion de gamma-carbolinas
ZA842335B (en) New five-membered nitrogen-containing heterocyclic compounds,processes for their preparation and their use as pets-combating agents
ES8801895A1 (es) Procedimiento para la obtencion de benzamidas
FR2473522B1 (es)
ES461779A1 (es) Procedimiento para la preparacion de lariloxi-3-amino-3-pro-panoles.
ES8602785A1 (es) Procedimiento para preparar derivados de pirazolpiridina
ES8604556A1 (es) Procedimiento para preparar derivados de flaveno y tioflave-no
ES8500223A1 (es) Un metodo de preparacion de derivados de oximas de halogenobenzofenonas.
DE1906194A1 (en) Antibiotic cephalosporin cpds.
FR2302326A1 (fr) Colorants disazoiques
FR2244514A1 (en) 1,2-Dihydroquinoline derivs - useful as anti-inflammatories
ES8703417A1 (es) Procedimiento para fabricar compuestos piperidinonicos eficaces en el tratamiento de cardiopatias
FR2381041A1 (fr) Hydroxyacides et medicaments les contenant
FR2081318A1 (en) 1,4 Benzodiazepine derivs. - sedatives muscle relaxants
GB1298210A (en) Improvements in or relating to dihalo-pyridazine derivatives